technetium has been researched along with carbocyanines in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blankesteijn, WM; Daemen, MJ; Fujimoto, A; Fujimoto, S; Hofstra, L; Isobe, S; Li, P; Lovhaug, D; Narula, J; Narula, N; Petrov, A; Pitt, B; Reutelingsperger, C; Smits, JF; van den Borne, SW; Vannan, MA; Wong, ND; Zandbergen, HR; Zannad, F | 1 |
| Mann, DL | 1 |
| Cheong, SJ; Jeong, HJ; Kim, DW; Kim, EM; Lee, CM; Lim, ST; Sohn, MH | 1 |
| Bhattacharyya, S; Bottaro, DP; Cecchi, F; Choyke, P; Elbuluk, O; Golla, M; Histed, S; Jagoda, EM; Kalen, J; Leeder, A; Raffensperger, K; Riffle, L; Szajek, LP; Williams, M; Wong, KJ; Xu, B | 1 |
| Banchero, A; Bertolini Zanatta, D; Buchpiguel, CA; Cabral, P; Camacho, X; Chammas, R; Fernández, M; Gambini, JP; García, MF; Machado, CL; Oddone, N; Riva, E; Rosal, C | 1 |
5 other study(ies) available for technetium and carbocyanines
| Article | Year |
|---|---|
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carbocyanines; Cardiovascular Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Spironolactone; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Molecular imaging and the failing heart: through the looking glass.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbocyanines; Cardiovascular Agents; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chitosan-DC101 conjugates.
Topics: Animals; Antibodies, Monoclonal; Carbocyanines; Cells, Cultured; Chitosan; Female; Hindlimb; Humans; Ischemia; Mice; Mice, Inbred BALB C; Microvessels; Molecular Imaging; Muscle, Skeletal; Neovascularization, Physiologic; Protein Isoforms; Radionuclide Imaging; Receptors, Vascular Endothelial Growth Factor; Technetium | 2010 |
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.
Topics: Animals; Carbocyanines; Cell Line, Tumor; Humans; Indoles; Mice; Neoplasms; Organotechnetium Compounds; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Spectrometry, Fluorescence; Staining and Labeling; Sulfones; Technetium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
Topics: Animals; Antigens, CD20; Carbocyanines; Cell Line, Tumor; Diagnostic Uses of Chemicals; Female; Humans; Lymphoma, Non-Hodgkin; Mice, Inbred BALB C; Molecular Imaging; Radiopharmaceuticals; Rituximab; Single Photon Emission Computed Tomography Computed Tomography; Technetium; Tissue Distribution | 2017 |